As such, this retrospective study aimed to assess fall/fracture-related outcomes in people with type 2 diabetes aged 50 years and older treated with the longer-acting basal insulin Gla-300 vs the long-acting basal insulins Gla-100 or IDet 100 U/mL, or NPH insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.